IPO - Regen BioPharma Inc

Form Type: 253G1

Filing Date: 2025-02-24

Corporate Action: Ipo

Type: New

Accession Number: 000149315225008067

Filing Summary: Regen BioPharma, Inc. filed an offering circular supplement on February 24, 2025, relating to an offering of up to 10,000,000 shares of its common stock under Tier I of Regulation A+. The offering circular aims to inform accredited investors about the securities being offered, stating the price per share is $0.04, with a maximum offering amount of $400,000. The document provides updates regarding the registration of the offering in various states, including Colorado, Delaware, and New York. The offering will commence within two days of qualification by the SEC and will terminate 90 days after qualification. The company has disclosed critical financial information, including total liabilities of $5,371,640 and the total stockholders' equity deficit of $5,194,029 as of September 30, 2024. There are significant risks associated with the investment, including doubts about the company's ability to continue as a going concern, the early stages of product development, and reliance on additional funding for operations. The document emphasizes the necessity for potential investors to consult the complete Offering Circular for comprehensive information prior to investing, highlighting no assurance of profitability or government approval for any products in development.

Document Link: View Document

Form Type: CORRESP

Filing Date: 2024-12-09

Corporate Action: Ipo

Type: New

Accession Number: 000149315224049269

Filing Summary: Regen BioPharma, Inc. requested the qualification of its offering statement on Form 1-A/A, file number 024-12505, set for 9:30 a.m. Eastern Time on December 10, 2024. The company acknowledges the Commission's right to take action regarding the filing and retains responsibility for the disclosure's adequacy and accuracy. Additionally, it confirms that at least one state has declared the offering 'Effective or Cleared for Sale' upon the SEC's qualification.

Document Link: View Document